GlassScriptPhysician profile
Monique Thammavong
NPI 1275932253
$4,013.21
in general payments reported to CMS, 2019-2025
31 companies · $740 in 2025
The $740 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $722 · 2022: $1,012 · 2023: $775 · 2024: $764 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $526.07 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $359.92 | 2022-2024 | Repatha, Otezla, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $224.66 | 2022 | |
| Pfizer INC. | $150.96 | 2021-2024 | |
| Novo Nordisk INC | $126.30 | 2021-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $125.30 | 2021-2024 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $124.94 | 2021 | |
| Stryker Corporation | $121.46 | 2025 | Flowtriever |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.91 | 2021-2025 | Xifaxan, Trulance |
| Vertex Pharmaceuticals Incorporated | $86.95 | 2025 | |
| Exact Sciences Corporation | $82.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $75.27 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $74.86 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $73.61 | 2021-2025 | Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $70.56 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.79 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $57.34 | 2022-2025 | |
| Axsome Therapeutics, INC. | $53.87 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $47.57 | 2021-2023 | Gvoke Hypopen |
| Abbott Laboratories | $45.61 | 2022-2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.01 | 2021-2022 | |
| Almatica Pharma LLC | $36.52 | 2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $33.34 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $24.63 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $20.57 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $18.72 | 2023 | |
| Sunovion Pharmaceuticals INC. | $18.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.57 | 2021 | |
| Halozyme INC | $14.19 | 2023 | |
| Dexcom, INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Thammavong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.